Semaglutide

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk for the treatment of type 2 diabetes and obesity. By mimicking the effects of endogenous GLP-1, it enhances insulin secretion, inhibits glucagon release, delays gastric emptying, and reduces appetite—resulting in improved glycemic control and significant weight loss. Available under the brand names Ozempic, Wegovy, and Rybelsus, semaglutide is offered in both injectable and oral formulations. Clinical trials have demonstrated its efficacy in reducing blood glucose levels and body weight, positioning it as a cornerstone therapy in metabolic disease management.

Ways to purchase:

Rejuv-rx utilizes an Institutional Review Board (IRB) through Cellular Peptide. Rejuv-RX is dedicated to the advancement and improvement of the healthcare industry. We have partnered with an Institutional Review Board (IRB) that assists in our research studies, which are submitted biannually.

Participation in these studies enables us to collect research data to improve and monitor peptide usage and outcomes. We offer our clients the option to purchase peptides utilizing our review board and help track results. To get started, just fill out the form to gain access to the portal. 

If you choose to opt out of our IRB, then understand Product Usage: THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only.

All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused, or mislabeled as a drug, food, or cosmetic.

You can find a video on how to reconstitute your peptides here.

You can find a video on how to inject your peptides here.